FDA Approved: PRADAXA — Original Application (Boehringer Ingelheim Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved Pradaxa (dabigatran etexilate mesylate) under an original NDA from Boehringer Ingelheim Pharmaceuticals Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Nonvalvular Atrial Fibrillation
• Pulmonary Embolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

ORIG AP for PRADAXA (DABIGATRAN ETEXILATE MESYLATE)